U
OCRX

UBS’s Ocera Therapeutics, Inc. OCRX Stock Holding History

UBS’s Portfolio OCRX Stock Details OCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-27,437
Closed -$289K – 11087
2014
Q1 		$289K Buy
+27,437
New +$392K ﹤0.01% 4799
2013
Q4 		– Sell
-389
Closed -$3K – 11042
2013
Q3 		$3K Sell
389
-2,422
-86% -$19.5K ﹤0.01% 9835
2013
Q2 		$16K Buy
+2,811
New +$17.5K ﹤0.01% 8167

Other funds holding OCRX

VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

UBS's OCRX Position: Q2 2014 in Review

UBS sold out of Ocera Therapeutics, Inc. (OCRX) in Q2 2014, closing a stake of 27,437 shares — an estimated $289K sold.

UBS first reported a position in OCRX in Q2 2013 and held it in 3 quarters. The position peaked at $289K in Q1 2014. 33 funds tracked by Wall St. Rank hold OCRX as of Q2 2014.

  • UBS reported no remaining Ocera Therapeutics, Inc. position as of Q2 2014 after selling out during the quarter.
  • UBS sold 27,437 Ocera Therapeutics, Inc. shares in Q2 2014, an estimated $289K.
  • UBS first reported a position in Ocera Therapeutics, Inc. in Q2 2013 and held it in 3 quarters.
  • UBS's Ocera Therapeutics, Inc. position peaked at $289K in Q1 2014.
  • 33 funds tracked by Wall St. Rank held Ocera Therapeutics, Inc. as of Q2 2014.

Based on UBS's 13F filing for Q2 2014, filed 14 Aug 2014.